Amgen will buy Micromet for $1.16 billion

01/26/2012 | Genetic Engineering & Biotechnology News

Amgen's acquisition of Micromet for $11 a share was approved by the boards of both companies. The cash transaction, worth about $1.16 billion, gives Amgen access to Micromet's antibody technology Bispecific T-cell Engager and its blood cancer drug candidate blinatumomab.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
Chief Executive Officer
UCare Minnesota
Minneapolis, MN